Inside ST-elevation myocardial infarction by monitoring concentrations of cardiovascular risk biomarkers in blood.

Background: No information is available on the optimal sampling time to catch the highest increase for biomarkers whose elevation after ST-elevation myocardial infarction (STEMI) is prognostic for adverse events. This study aimed to investigate release kinetics and peak times of cardiac troponin I (cTnI), C-reactive protein (CRP), B-type natriuretic peptide (BNP), chromogranin A (CgA) and cystatin C (CyC) in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).

Methods: Blood concentrations of cTnI, CRP, BNP, CgA and CyC were measured before and 6 h, 24 h, and 48 h after PPCI in 84 STEMI patients.

Plasma B-type natriuretic peptide in dialyzed patients: marker of cardiovascular disease or link to plasma refilling.

Background: B-type natriuretic peptide (BNP) is released in response to extracellular volume and blood pressure (BP) overload and is a risk factor for cardiovascular diseases (CVD). BNP is increased in dialyzed patients (HDpts). The aim of this study was to evaluate the relationships between BNP and renin, aldosterone and blood volume reduction rate (BV/WL), with the presence of CVD and mortality.

Impact of calibration fitting models on the clinical value of chromogranin A.

Background: The clinical relevance of chromogranin A (CgA) concentrations depends on the analytical performance of the assay. The goal of the present study was to define the clinical involvements in CgA calibration models by evaluating the confidence intervals (CIs) for values from patients who were undergoing monitoring for disease.

Methods: Thirty calibration curves for the CgA assay [immunoradiometric assay (IRMA), (CIS-BIO)] were built using linear regression (LR), and four-parameter logistic models were used to estimate CIs for patient concentrations.

Different patterns of NT-proBNP secretion in acute coronary syndromes.

Unlabelled: BACKGROUND; The wide variability of NT-proBNP levels in acute coronary syndromes could arise from sympathetic activation and glomerular impairment. The aim of the study was to investigate, in this setting, the dependence of NT-proBNP from Chromogranin A (CgA) and Cystatin C (CC) levels, respectively assessing sympathetic activation and glomerular impairment.

Methods: In 132 patients, 90 ST elevation acute coronary syndrome (STE-ACS) and 42 non ST elevation acute coronary syndrome (NSTE-ACS), within 24 h from symptoms and with creatinine levels lower than 141.